{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:25:23Z","timestamp":1784150723221,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prostate cancer (PC) is the most common reproductive cancer in men and the third leading cause of cancer death among men worldwide. Recently targeted therapy showed a significant therapeutic effect on PC, whereas finding more PC therapeutic target is still urgently needed. Melanoma-associated antigen-encoding C2 (MAGE-C2\/CT10), which have significant homology with the MAGE-C1\/CT-7 gene, was known to be involved in the development of a variety of tumors. However, the role and mechanism of MAGE-C2\/CT10 in prostate cancer remains unclear. Herein, we found the high levels of MAGE-C2\/CT10 in highly metastatic prostate cancer. Our findings confirmed that the depletion of MAGE-C2\/CT10 suppressed the growth of PC cells, and restrained PC cell migration and invasion in vitro. We noticed MAGE-C2\/CT10 could stimulate c-Myc expression via FBP1, and further contributed to PC cell proliferation and motility. Performing in vivo assays, we demonstrated MAGE-C2\/CT10 promoted tumor growth and metastasis of PC cells in mice. Collectively, we found the abnormal expression of MAGE-C2\/CT10 in PC, and revealed the regulatory mechanism underlying MAGE-C2\/CT10 promoting PC progression and metastasis.<\/jats:p>","DOI":"10.1007\/s11010-020-03814-7","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T18:15:30Z","timestamp":1600193730000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["RETRACTED ARTICLE: MAGE-C2\/CT10 promotes growth and metastasis through upregulating c-Myc expression in prostate cancer"],"prefix":"10.1007","volume":"476","author":[{"given":"Jun","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8076-7372","authenticated-orcid":false,"given":"Bei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"3814_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0290-3","author":"NG Zaorsky","year":"2020","unstructured":"Zaorsky NG, Kishan AU (2020) Salvage therapy at biochemical recurrence of prostate cancer. Nat Rev Urol. https:\/\/doi.org\/10.1038\/s41585-020-0290-3","journal-title":"Nat Rev Urol"},{"key":"3814_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002942","author":"A Ozkan","year":"2020","unstructured":"Ozkan A, Ucar B, Seymen H, Yildiz Yarar Y, Falay FO, Demirkol MO (2020) Posttherapeutic critical organ dosimetry of extensive 177Lu-PSMA inhibitor therapy with metastatic castration-resistant prostate cancer: one center results. Clin Nucl Med. https:\/\/doi.org\/10.1097\/RLU.0000000000002942","journal-title":"Clin Nucl Med"},{"key":"3814_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0206-6","author":"MJ Connor","year":"2020","unstructured":"Connor MJ, Gorin MA, Ahmed HU, Nigam R (2020) Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-020-0206-6","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"3814_CR4","doi-asserted-by":"publisher","first-page":"e0229263","DOI":"10.1371\/journal.pone.0229263","volume":"15","author":"JM Liu","year":"2020","unstructured":"Liu JM, Liu YP, Chuang HC, Wu CT, Su YL, Hsu RJ (2020) Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders. PLoS ONE 15(2):e0229263. https:\/\/doi.org\/10.1371\/journal.pone.0229263","journal-title":"PLoS ONE"},{"issue":"32","key":"3814_CR5","doi-asserted-by":"publisher","first-page":"13493","DOI":"10.1073\/pnas.0906840106","volume":"106","author":"A Grigoriadis","year":"2009","unstructured":"Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ, Jungbluth AA, Miller LD, Clouston D, Cebon J, Old LJ, Lakhani SR, Simpson AJ, Neville AM (2009) CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA 106(32):13493\u201313498. https:\/\/doi.org\/10.1073\/pnas.0906840106","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3814_CR6","doi-asserted-by":"publisher","first-page":"15304","DOI":"10.1038\/s41598-018-33601-w","volume":"8","author":"Y Gao","year":"2018","unstructured":"Gao Y, Kardos J, Yang Y, Tamir TY, Mutter-Rottmayer E, Weissman B, Major MB, Kim WY, Vaziri C (2018) The cancer\/testes (CT) antigen HORMAD1 promotes homologous recombinational DNA repair and radioresistance in lung adenocarcinoma cells. Sci Rep 8(1):15304. https:\/\/doi.org\/10.1038\/s41598-018-33601-w","journal-title":"Sci Rep"},{"issue":"1","key":"3814_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/1097-0215(20000701)87:1<55::AID-IJC8>3.0.CO;2-J","volume":"87","author":"S Lucas","year":"2000","unstructured":"Lucas S, De Plaen E, Boon T (2000) MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int J Cancer 87(1):55\u201360","journal-title":"Int J Cancer"},{"issue":"2","key":"3814_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ijc.23966","volume":"124","author":"MO Riener","year":"2009","unstructured":"Riener MO, Wild PJ, Soll C, Knuth A, Jin B, Jungbluth A, Hellerbrand C, Clavien PA, Moch H, Jochum W (2009) Frequent expression of the novel cancer testis antigen MAGE-C2\/CT-10 in hepatocellular carcinoma. Int J Cancer 124(2):352\u2013357. https:\/\/doi.org\/10.1002\/ijc.23966","journal-title":"Int J Cancer"},{"issue":"1","key":"3814_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00262-012-1376-4","volume":"62","author":"F de Carvalho","year":"2013","unstructured":"de Carvalho F, Alves VL, Braga WM, Xavier CV Jr, Colleoni GW (2013) MAGE-C1\/CT7 and MAGE-C2\/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. Cancer Immunol Immunother 62(1):191\u2013195. https:\/\/doi.org\/10.1007\/s00262-012-1376-4","journal-title":"Cancer Immunol Immunother"},{"key":"3814_CR10","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1038\/bcj.2014.31","volume":"4","author":"H Reinhard","year":"2014","unstructured":"Reinhard H, Yousef S, Luetkens T, Fehse B, Berdien B, Kroger N, Atanackovic D (2014) Cancer\u2013testis antigen MAGE-C2\/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients. Blood Cancer J 4:e212. https:\/\/doi.org\/10.1038\/bcj.2014.31","journal-title":"Blood Cancer J"},{"issue":"3","key":"3814_CR11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/jid.2012.355","volume":"133","author":"N Bhatia","year":"2013","unstructured":"Bhatia N, Xiao TZ, Rosenthal KA, Siddiqui IA, Thiyagarajan S, Smart B, Meng Q, Zuleger CL, Mukhtar H, Kenney SC, Albertini MR, Jack Longley B (2013) MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair. J Investig Dermatol 133(3):759\u2013767. https:\/\/doi.org\/10.1038\/jid.2012.355","journal-title":"J Investig Dermatol"},{"issue":"7","key":"3814_CR12","doi-asserted-by":"publisher","first-page":"e21366","DOI":"10.1371\/journal.pone.0021366","volume":"6","author":"L von Boehmer","year":"2011","unstructured":"von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T, Sulser T, Jungbluth AA, Old LJ, Kristiansen G, van den Broek M, Moch H, Knuth A, Wild PJ (2011) MAGE-C2\/CT10 protein expression is an independent predictor of recurrence in prostate cancer. PLoS ONE 6(7):e21366. https:\/\/doi.org\/10.1371\/journal.pone.0021366","journal-title":"PLoS ONE"},{"issue":"4","key":"3814_CR13","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1038\/oncsis.2017.21","volume":"6","author":"X Jin","year":"2017","unstructured":"Jin X, Pan Y, Wang L, Zhang L, Ravichandran R, Potts PR, Jiang J, Wu H, Huang H (2017) MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation. Oncogenesis 6(4):e312. https:\/\/doi.org\/10.1038\/oncsis.2017.21","journal-title":"Oncogenesis"},{"issue":"12","key":"3814_CR14","first-page":"2650","volume":"9","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Liu M, Hu Q, Xu W, Liu W, Sun Q, Ye Z, Fan G, Xu X, Yu X, Ji S, Qin Y (2019) FGFBP1, a downstream target of the FBW7\/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. Am J Cancer Res 9(12):2650\u20132664","journal-title":"Am J Cancer Res"},{"issue":"2","key":"3814_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/14737159.2020.1707669","volume":"20","author":"R Iacovelli","year":"2020","unstructured":"Iacovelli R, Ciccarese C, Schinzari G, Rossi E, Maiorano BA, Astore S, D\u2019Angelo T, Cannella A, Pirozzoli C, Teberino MA, Pierconti F, Martini M, Tortora G (2020) Biomarkers of response to advanced prostate cancer therapy. Expert Rev Mol Diagn 20(2):195\u2013205. https:\/\/doi.org\/10.1080\/14737159.2020.1707669","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"3814_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40798-020-0242-8","volume":"6","author":"T Lam","year":"2020","unstructured":"Lam T, Birzniece V, McLean M, Gurney H, Hayden A, Cheema BS (2020) The adverse effects of androgen deprivation therapy in prostate cancer and the benefits and potential anti-oncogenic mechanisms of progressive resistance training. Sports Med Open 6(1):13. https:\/\/doi.org\/10.1186\/s40798-020-0242-8","journal-title":"Sports Med Open"},{"issue":"5","key":"3814_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pros.23955","volume":"80","author":"MC Markowski","year":"2020","unstructured":"Markowski MC, Shenderov E, Eisenberger MA, Kachhap S, Pardoll DM, Denmeade SR, Antonarakis ES (2020) Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. Prostate 80(5):407\u2013411. https:\/\/doi.org\/10.1002\/pros.23955","journal-title":"Prostate"},{"issue":"3","key":"3814_CR18","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3892\/ol.2017.5665","volume":"13","author":"X Chen","year":"2017","unstructured":"Chen X, Wang L, Liu J, Huang L, Yang L, Gao Q, Shi X, Li J, Li F, Zhang Z, Zhao S, Zhang B, Van der Bruggen P, Zhang Y (2017) Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer. Oncol Lett 13(3):1609\u20131618. https:\/\/doi.org\/10.3892\/ol.2017.5665","journal-title":"Oncol Lett"},{"key":"3814_CR19","doi-asserted-by":"publisher","first-page":"2325987","DOI":"10.1155\/2016\/2325987","volume":"2016","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Xu WT, Shalieer T (2016) Pilot study on MAGE-C2 as a potential biomarker for triple-negative breast cancer. Dis Markers 2016:2325987. https:\/\/doi.org\/10.1155\/2016\/2325987","journal-title":"Dis Markers"},{"issue":"6","key":"3814_CR20","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.4049\/jimmunol.1502024","volume":"197","author":"A Kunert","year":"2016","unstructured":"Kunert A, van Brakel M, van Steenbergen-Langeveld S, da Silva M, Coulie PG, Lamers C, Sleijfer S, Debets R (2016) MAGE-C2-specific TCRs combined with epigenetic drug-enhanced antigenicity yield robust and tumor-selective T cell responses. J Immunol 197(6):2541\u20132552. https:\/\/doi.org\/10.4049\/jimmunol.1502024","journal-title":"J Immunol"},{"issue":"6","key":"3814_CR21","doi-asserted-by":"publisher","first-page":"656","DOI":"10.7150\/jca.13674","volume":"7","author":"X Song","year":"2016","unstructured":"Song X, Song W, Wang Y, Wang J, Li Y, Qian X, Pang X, Zhang Y, Yin Y (2016) MicroRNA-874 functions as a tumor suppressor by targeting cancer\/testis antigen HCA587\/MAGE-C2. J Cancer 7(6):656\u2013663. https:\/\/doi.org\/10.7150\/jca.13674","journal-title":"J Cancer"},{"issue":"39","key":"3814_CR22","doi-asserted-by":"publisher","first-page":"42028","DOI":"10.18632\/oncotarget.5973","volume":"6","author":"J Hao","year":"2015","unstructured":"Hao J, Song X, Wang J, Guo C, Li Y, Li B, Zhang Y, Yin Y (2015) Cancer\u2013testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E. Oncotarget 6(39):42028\u201342039. https:\/\/doi.org\/10.18632\/oncotarget.5973","journal-title":"Oncotarget"},{"issue":"8","key":"3814_CR23","first-page":"1722","volume":"9","author":"C Yang","year":"2019","unstructured":"Yang C, Zhu S, Yang H, Deng S, Fan P, Li M, Jin X (2019) USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1. Am J Cancer Res 9(8):1722\u20131733","journal-title":"Am J Cancer Res"},{"issue":"3","key":"3814_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ccr.2013.01.022","volume":"23","author":"C Dong","year":"2013","unstructured":"Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, Lin Y, Yao J, Shi J, Kang T, Lorkiewicz P, St Clair D, Hung MC, Evers BM, Zhou BP (2013) Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23(3):316\u2013331. https:\/\/doi.org\/10.1016\/j.ccr.2013.01.022","journal-title":"Cancer Cell"},{"issue":"4","key":"3814_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41388-018-0469-8","volume":"38","author":"Q Li","year":"2019","unstructured":"Li Q, Wei P, Wu J, Zhang M, Li G, Li Y, Xu Y, Li X, Xie D, Cai S, Xie K, Li D (2019) The FOXC1\/FBP1 signaling axis promotes colorectal cancer proliferation by enhancing the Warburg effect. Oncogene 38(4):483\u2013496. https:\/\/doi.org\/10.1038\/s41388-018-0469-8","journal-title":"Oncogene"},{"issue":"11","key":"3814_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12032-019-1317-6","volume":"36","author":"H Dong","year":"2019","unstructured":"Dong H, Hu J, Wang L, Qi M, Lu N, Tan X, Yang M, Bai X, Zhan X, Han B (2019) SOX4 is activated by C-MYC in prostate cancer. Med Oncol 36(11):92. https:\/\/doi.org\/10.1007\/s12032-019-1317-6","journal-title":"Med Oncol"},{"issue":"2","key":"3814_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2174\/1568009619666191118113220","volume":"20","author":"F Peng","year":"2020","unstructured":"Peng F, Yang C, Kong Y, Huang X, Chen Y, Zhou Y, Xie X, Liu P (2020) CDK12 promotes breast cancer progression and maintains stemness by activating c-myc\/beta-catenin Signaling. Curr Cancer Drug Targets 20(2):156\u2013165. https:\/\/doi.org\/10.2174\/1568009619666191118113220","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"3814_CR28","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.7150\/thno.37621","volume":"10","author":"W Sun","year":"2020","unstructured":"Sun W, Li J, Zhou L, Han J, Liu R, Zhang H, Ning T, Gao Z, Liu B, Chen X, Ba Y (2020) The c-Myc\/miR-27b-3p\/ATG10 regulatory axis regulates chemoresistance in colorectal cancer. Theranostics 10(5):1981\u20131996. https:\/\/doi.org\/10.7150\/thno.37621","journal-title":"Theranostics"},{"key":"3814_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/cancers11111785","volume":"11","author":"CY Lin","year":"2019","unstructured":"Lin CY, Wang BJ, Chen BC, Tseng JC, Jiang SS, Tsai KK, Shen YY, Yuh CH, Sie ZL, Wang WC, Kung HJ, Chuu CP (2019) Histone demethylase KDM4C stimulates the proliferation of prostate cancer cells via activation of AKT and c-Myc. Cancers 11:11. https:\/\/doi.org\/10.3390\/cancers11111785","journal-title":"Cancers"},{"issue":"2","key":"3814_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbrc.2018.08.069","volume":"504","author":"X Qu","year":"2018","unstructured":"Qu X, Sun J, Zhang Y, Li J, Hu J, Li K, Gao L, Shen L (2018) c-Myc-driven glycolysis via TXNIP suppression is dependent on glutaminase-MondoA axis in prostate cancer. Biochem Biophys Res Commun 504(2):415\u2013421. https:\/\/doi.org\/10.1016\/j.bbrc.2018.08.069","journal-title":"Biochem Biophys Res Commun"}],"updated-by":[{"DOI":"10.1007\/s11010-023-04820-1","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"record-id":"46408"},{"DOI":"10.1007\/s11010-020-03958-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000}},{"DOI":"10.1007\/s11010-023-04820-1","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000}}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-020-03814-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-020-03814-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-020-03814-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T09:05:58Z","timestamp":1690448758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-020-03814-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["3814"],"URL":"https:\/\/doi.org\/10.1007\/s11010-020-03814-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11010-020-03958-6","asserted-by":"object"}]},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11010-020-03958-6","URL":"https:\/\/doi.org\/10.1007\/s11010-020-03958-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11010-023-04820-1","URL":"https:\/\/doi.org\/10.1007\/s11010-023-04820-1","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors state that there are no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Animal experiment in this study was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University for the Use of Animals and conducted in accordance with the National Institutes of Health Laboratory Animal Care and Use Guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}